Visitors Now:
Total Visits:
Total Stories:

By Next Big Future (Reporter)
Contributor profile | More stories

Story Views
Now:
Last Hour:
Last 24 Hours:
Total:

DARPA Foam Could Increase Survival Rate for Victims of Internal Hemorrhaging

Monday, December 10, 2012 16:41

% of readers think this story is Fact. Add your two cents.

(Before It's News)

From NextBigFuture.com

echnology developed under DARPA’s Wound Stasis System program resulted in 72 percent survival rate at three hours post-injury in testing.

The Department of Defense’s medical system aspires to a standard known as the “Golden Hour” that dictates that troops wounded on the battlefield are moved to advanced-level treatment facilities within the first 60 minutes of being wounded. In advance of transport, initial battlefield medical care administered by first responders is often critical to injured servicemembers’ survival. In the case of internal abdominal injuries and resulting internal hemorrhaging, however, there is currently little that can be done to stanch bleeding before the patients reach necessary treatment facilities; internal wounds cannot be compressed the same way external wounds can, and tourniquets or hemostatic dressings are unsuitable because of the need to visualize the injury. The resulting blood loss often leads to death from what would otherwise be potentially survivable wounds.

DARPA launched its Wound Stasis System program in 2010 in the hopes of finding a technological solution that could mitigate damage from internal hemorrhaging. The program sought to identify a biological mechanism that could discriminate between wounded and healthy tissue, and bind to the wounded tissue. As the program evolved, an even better solution emerged: Wound Stasis performer Arsenal Medical, Inc. developed a foam-based product that can control hemorrhaging in a patient’s intact abdominal cavity for at least one hour, based on swine injury model data. The foam is designed to be administered on the battlefield by a combat medic, and is easily removable by doctors during surgical intervention at an appropriate facility, as demonstrated in testing.

B4INREMOTE-aHR0cDovLzQuYnAuYmxvZ3Nwb3QuY29tLy1TYWUyVS1pQXFTUS9VTVptSFo5cXBMSS9BQUFBQUFBQWdFMC9OSE5vVzlLdENNcy9zNDAwL1RyYXVtYV9BbmltYXRpb24uanBn

The foam-based product developed by Arsenal Medical for DARPA can be injected into a wounded servicemember on the battlefield to slow blood loss until the patient can be transported to an appropriate medical facility.